Becton, Dickinson And Company · NYSE:BDX
Becton, Dickinson And — Q3 2026 Earnings Presentation
23 slides from Becton, Dickinson And's earnings presentation, Aug 6, 2026
Slide 1: Q3 FY26 Earnings Presentation
Q3 FY26 Earnings Presentation August 6, 2026 Advancing the TM world of health
Slide 2: Caution Concerning Forward-looking Statements and Non-GAAP Financial Measures
Caution Concerning Forward-looking Statements This presentation and accompanying webcast contain certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s future prospects and performance, including, but not limited to, future revenues, margins,
Slide 3: Basis of Presentation
Basis of Presentation All dollar amounts presented are USD ($) in millions, unless otherwise indicated, except per share figures. FXN denotes currency-neutral basis. Revenue year-over-year change comparisons are on an FXN basis unless otherwise noted. References to “FY” refer to BD’s fiscal year, wh
Slide 4: Disciplined Execution Drives Q3 Outperformance
Disciplined Execution Drives Q3 Outperformance ✓ Delivered strong Q3 performance , reflecting a more focused New BD Revenue $5.0B +4.4% FXN ✓ Broad-based execution, with more than 90% of the business delivering high -single- digit revenue growth Adjusted ✓ Commercial excellence and investments drivi
Slide 5: Driving Competitive Wins, Innovation Speed and Productivity
Driving Competitive Wins, Innovation Speed and Productivity Compete Innovate Deliver + MMS: drove continued share gains in BD Alaris + Increasing cadence of high-impact launches + ~8% gross productivity improvements in our with now over 200 bps YTD that expand our addressable markets, plants in Q3 F
Slide 6: High-Impact Launches Expanding Addressable Markets
High-Impact Launches Expanding Addressable Markets Expansion into a new venous segment Advancing stone lithotripsy and soft Revolutionizing hemodynamic monitoring with novel stent graft system tissue applications with smarter non -invasive insights BD Liverty TIPS Stent Graft BD Elyra Thulium Fiber
Slide 7: Q3 FY26 Segment Revenue and Key Highlights
Q3 FY26 Segment Revenue and Key Highlights Medical Essentials Connected Care BioPharma Systems Interventional $1,675 $1,224 $670 $1,414 $629 $1,602 $1,166 $1,328 +3.2% +4.4% +5.2% +5.5% FXN FXN FXN FXN Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 Q3 FY25 Q3 FY26 • MDS: $1,164M; +1.6% FXN • MMS: $
Slide 8: Q3 FY26 Financial Summary: Revenues, Adjusted Margins and Adjusted EPS
Q3 FY26 Financial Summary: Revenues, Adjusted Margins and Adjusted EPS (As adjusted) $ in millions, except per share data Q3 FY26 Q3 FY25 Y/Y ∆ Revenues $4,983 $4,726 5.4% * FXN revenue growth 4.4% Gross Profit $2,705 $2,611 3.6% Gross margin 54.3% 55.3% (100 bps) SSG&A $1,232 $1,143 7.8% % of reven
Slide 9: Strong Cash Generation and Capital Allocation Strategy
Strong Cash Generation and Capital Allocation Strategy Supporting $3.1B in Shareholder Returns YTD +45% • YTD free cash flow improved YoY; reflects improved working capital and lower non-operational cash items • BD Excellence productivity gains are improving FCF; more firepower to execute discipline
Slide 10: Updating Full-Year FY26 Guidance on Broad-Based Momentum
Updating Full-Year FY26 Guidance on Broad-Based Momentum Guidance as of Guidance as of August 6, 2026 May 7, 2026 Guidance Considerations • Expect revenue growth toward the high-end of our low-single-digit range Revenue Growth (FXN) Low single-digit growth Low single-digit growth • For the full year
Slide 11: Summary
Summary ✓ Deliveredstrong Q3 performance , reflecting a more focused New BD ✓ Broad-based execution,with more than 90% of the business delivering high-single-digit revenue growth ✓ Commercial excellence and investments driving double -digit growth in key platforms , including Biologic Drug Delivery,
Slide 12: Appendix
Appendix Q3 FY26 EARNINGS PRESENTATION August 6, 2026 12
Slide 13: Advancing a Stronger, More Focused Pipeline of High-Impact Solutions
Advancing a Stronger, More Focused Pipeline of High-Impact Solutions Medical Essentials Connected Care BioPharma Systems Interventional BD Incada BD Alaris BD Pyxis Pro Connected Infusion System Dispensing Solution Care Platform BD Neopak BD Vystra BD Physioject PureWick Male and Flex PureWick Surgi
Slide 14: Corporate Sustainability: Together We Advance
Corporate Sustainability: Together We Advance FY25 Corporate Sustainability Report highlights : • Achieved a 24% reduction in Scopes 1 and 2 emissions (2019 baseline). • 50 BD sites now operate using 100% renewable energy; • Achieved $2.4M in annual energy savings through process/efficiency upgrades
Slide 15: Glossary
Glossary AI Artificial Intelligence GLP - 1 Glucagon - Like Peptide -1 R&D Research and Development APM Advanced Patient Monitoring HSD High - Single - Digit SM Specimen Management Shipping, Selling, General and B Billion ICU Intensive Care Unit SSG&A Administrative BPS BioPharma Systems IV Intraven
Slide 16: Supplemental Reconciliation – Revenues by Business Segments and Units
Supplemental Reconciliation – Revenues by Business Segments and Units For the Three Months Ended June 30, (Unaudited; $ in millions) (1) Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which were based on the nature of the
Slide 17: Supplemental Revenue Information – Revenues by Geographic Regions
Supplemental Revenue Information – Revenues by Geographic Regions For the Three Months Ended June30, (Unaudited; $ in millions) D=(A-B)/B E=(A-B-C)/B A B C % Change 2026 2025 FX Impact Reported FXN DEVELOPED MARKETS REVENUES $ 4,365 $ 4,113 $ 27 6.1 5.5 EMERGING MARKETS REVENUES 618 613 21 0.8 (2.6)
Slide 18: Supplemental Reconciliation – Reported Diluted EPS to Adjusted Diluted EPS
Supplemental Reconciliation – Reported Diluted EPS to Adjusted Diluted EPS For the Three Months Ended June 30, (Unaudited) (1) Includes amortization and other adjustments related to the purchase accounting for acquisitions. (2) Represents costs associated with integration and restructuring activitie
Slide 19: Supplemental Non-GAAP Reconciliation
Supplemental Non-GAAP Reconciliation For the Three Months Ended June 30, 2026 (Unaudited; $ in millions, except per share data) Purchase Product, Income tax Notes for Non- Reported accounting Integration Restructuring Separation- litigation, and benefit of Adjusted GAAP (GAAP) adjustments costs cost
Slide 20: Supplemental Non-GAAP Reconciliation
Supplemental Non-GAAP Reconciliation For the Three Months EndedJune 30, 2025 (Unaudited; $ in millions, except per share data) Purchase Product, Income tax Notes for Non- Reported accounting Integration Restructuring Transaction litigation, and benefit of Adjusted GAAP (GAAP) adjustments costs costs
Slide 21: Supplemental Non-GAAP Reconciliation
Supplemental Non-GAAP Reconciliation Change in Three Months Ended June 30, 2026 Compared With Three Months Ended June 30, 2025 (Unaudited; $ in millions, except per share data) (A) (B) (C) = (A) - (B) (D) = (C) / (B) Adjusted Adjusted Adjusted Adjusted (Non-GAAP) (Non-GAAP) (Non-GAAP) (Non-GAAP) Q3
Slide 22: Supplemental Reconciliation – Net Leverage and Free Cash Flow
Supplemental Reconciliation – Net Leverage and Free Cash Flow Last Twelve Months Ended June 30, 2026 For the Nine Months Ended June 30, 2026 (Unaudited; Amounts (Unaudited; Amountsininmillions) millions) (Unaudited; Amounts in millions) A B C=A-B D=C/B Reported GAAP Net Income from Continuing Operat
Slide 23: FY2026 Guidance Reconciliation
FY2026 Guidance Reconciliation (1) Includes amortization and other adjustments related to the purchase accounting for acquisitions. (2) Represents costs associated with integration and restructuring activities. (3) Represents transaction costs incurred in connection with the Advanced Patient Monitor
Becton, Dickinson and Company — Q3 2026 Earnings Presentation on 6ix